[go: up one dir, main page]

MX2018008026A - Una formulacion de conjugado de crecimiento humano de accion prolongada. - Google Patents

Una formulacion de conjugado de crecimiento humano de accion prolongada.

Info

Publication number
MX2018008026A
MX2018008026A MX2018008026A MX2018008026A MX2018008026A MX 2018008026 A MX2018008026 A MX 2018008026A MX 2018008026 A MX2018008026 A MX 2018008026A MX 2018008026 A MX2018008026 A MX 2018008026A MX 2018008026 A MX2018008026 A MX 2018008026A
Authority
MX
Mexico
Prior art keywords
long
growth hormone
human growth
phase preparation
novel liquid
Prior art date
Application number
MX2018008026A
Other languages
English (en)
Inventor
Kyu Lim Hyung
Min Bae Sung
Chang Kwon Se
Young Dong Joo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2018008026A publication Critical patent/MX2018008026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente invención se refiere a una formulación líquida de un conjugado de hormona del crecimiento humana y a un procedimiento de preparación de la misma.
MX2018008026A 2015-12-30 2016-12-30 Una formulacion de conjugado de crecimiento humano de accion prolongada. MX2018008026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150189919A KR20170079409A (ko) 2015-12-30 2015-12-30 지속형 인간 성장 호르몬 결합체의 신규 액상 제제
PCT/KR2016/015534 WO2017116191A2 (ko) 2015-12-30 2016-12-30 지속형 인간 성장 호르몬 결합체의 신규 액상 제제

Publications (1)

Publication Number Publication Date
MX2018008026A true MX2018008026A (es) 2018-11-29

Family

ID=59227383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008026A MX2018008026A (es) 2015-12-30 2016-12-30 Una formulacion de conjugado de crecimiento humano de accion prolongada.

Country Status (15)

Country Link
US (1) US20190022183A1 (es)
EP (1) EP3398586A4 (es)
JP (1) JP2019500390A (es)
KR (1) KR20170079409A (es)
CN (1) CN108697642A (es)
AR (1) AR107276A1 (es)
AU (1) AU2016382383A1 (es)
BR (1) BR112018013535A2 (es)
CA (1) CA3009627A1 (es)
HK (1) HK1258240A1 (es)
IL (1) IL260316A (es)
MX (1) MX2018008026A (es)
RU (1) RU2018125963A (es)
TW (1) TW201735940A (es)
WO (1) WO2017116191A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200029374A (ko) * 2018-09-10 2020-03-18 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
EP3937904A1 (en) * 2019-03-15 2022-01-19 Eli Lilly and Company Preserved formulations
WO2021085518A1 (ja) * 2019-10-30 2021-05-06 Ｊｃｒファーマ株式会社 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1044471A1 (en) * 1999-05-31 2002-10-25 Mitsubishi Chemical Corporation Freeze dried hgf preparations
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
US8729015B2 (en) * 2007-12-21 2014-05-20 Merck Patent Gmbh Solid lipid microcapsules containing growth hormone inner core microparticles
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
HK1225976A1 (en) * 2013-09-27 2017-09-22 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation

Also Published As

Publication number Publication date
JP2019500390A (ja) 2019-01-10
WO2017116191A3 (ko) 2018-03-08
CN108697642A (zh) 2018-10-23
WO2017116191A2 (ko) 2017-07-06
IL260316A (en) 2019-02-28
US20190022183A1 (en) 2019-01-24
RU2018125963A (ru) 2020-01-30
HK1258240A1 (en) 2019-11-08
EP3398586A4 (en) 2019-08-07
CA3009627A1 (en) 2017-07-06
TW201735940A (zh) 2017-10-16
AR107276A1 (es) 2018-04-11
KR20170079409A (ko) 2017-07-10
EP3398586A2 (en) 2018-11-07
AU2016382383A1 (en) 2018-07-26
BR112018013535A2 (pt) 2018-12-04

Similar Documents

Publication Publication Date Title
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
IN2014CH00247A (es)
PH12016501414B1 (en) Long-acting insulin and use thereof
AU2017242867A8 (en) Vortioxetine pamoic acid salt and crystal form thereof
IN2013MU00646A (es)
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
NZ735736A (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
SG11201911164WA (en) Method for preparing intermediate of 4-methoxypyrrole derivative
PL3717457T4 (pl) Sposób wytwarzania enzalutamidu z wykorzystaniem nowych związków pośrednich
MX372682B (es) Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
EA201691741A1 (ru) Фармацевтическая композиция
MX2018008026A (es) Una formulacion de conjugado de crecimiento humano de accion prolongada.
PH12018500872A1 (en) Innovative preparation and crystallization of iosimenol
ZA201507312B (en) Improved preparation method for high-yield production of physiologically active polypeptide conjugate
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
IL279410A (en) Process for preparing Quinmark
PL3672926T3 (pl) Sposób do wytwarzania rozpuszczalnych formulacji nawozów
IN2014CH01391A (es)
DK3649219T3 (en) Process for the preparation of a hydrogenated fat composition
AU2017904243A0 (en) Method to improve crop yields
TWI562978B (en) Method for preparation of 1,4-cyclohexanedialkanol